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Abstract: Since the introduction of allergen immunotherapy (AIT) over 100 years ago, focus has been
on standardization of allergen extracts, with reliable molecular composition of allergens receiving the
highest attention. While adjuvants play a major role in European AIT, they have been less well studied.
In this Position Paper we summarize current unmet needs of adjuvants in AIT citing current evidence.
Four adjuvants are used in products marketed in Europe: aluminium hydroxide (Al(OH)3) is the most
frequently used adjuvant, with microcrystalline tyrosine (MCT), monophosphoryl lipid A (MPLA) and
calcium phosphate (CaP) used less frequently. Recent studies on humans, and using mouse models, have
characterized in part the mechanisms of action of adjuvants on pre‐existing immune responses. AIT
differs from prophylactic vaccines that provoke immunity to infectious agents, as in allergy the patient
is pre‐sensitized to the allergen. The intended mode of action of adjuvants is to simultaneously enhance
the immunogenicity of the allergen, while precipitating the allergen at the injection site to reduce the
risk of anaphylaxis. Contrasting immune effects are seen with different adjuvants. Aluminium hydroxide
initially boosts Th2 responses, while the other adjuvants utilised in AIT redirect the Th2 immune response
toward Th1 immunity. After varying lengths of time, each of the adjuvants supports tolerance. Further
studies of the mechanisms of action of adjuvants may advise shorter treatment periods than the current
three‐to‐five‐year regimens, enhancing patient adherence. Improved lead compounds from the adjuvant
pipeline are under development and are explored for their capacity to fill this unmet need.
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Abstract 
Since the introduction of allergen immunotherapy (AIT) over 100 years ago, focus has been on 
standardization of allergen extracts, with reliable molecular composition of allergens receiving the 
highest attention. While adjuvants play a major role in European AIT, they have been less well 
studied. In this Position Paper we summarize current unmet needs of adjuvants in AIT citing 
current evidence. Four adjuvants are used in products marketed in Europe: aluminium hydroxide 
(Al(OH)3) is the most frequently used adjuvant, with microcrystalline tyrosine (MCT), 
monophosphoryl lipid A (MPLA) and calcium phosphate (CaP) used less frequently. Recent 
studies on humans, and using mouse models, have characterized in part the mechanisms of 
action of adjuvants on pre-existing immune responses.  AIT differs from prophylactic vaccines 
that provoke immunity to infectious agents, as in allergy the patient is pre-sensitized to the 
allergen. The intended mode of action of adjuvants is to simultaneously enhance the 
immunogenicity of the allergen, while precipitating the allergen at the injection site to reduce the 
risk of anaphylaxis. Contrasting immune effects are seen with different adjuvants. Aluminium 
hydroxide initially boosts Th2 responses, while the other adjuvants utilised in AIT redirect the Th2 
immune response toward Th1 immunity. After varying lengths of time, each of the adjuvants 
supports tolerance. Further studies of the mechanisms of action of adjuvants may advise shorter 
treatment periods than the current three-to-five-year regimens, enhancing patient adherence. 
Improved lead compounds from the adjuvant pipeline are under development and are explored 
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1. Introduction 
Allergen immunotherapy (AIT) is a long-standing and effective intervention to induce tolerance in 
a hypersensitive patient1 and it is currently the only disease-modifying, potentially curative 
treatment option for allergy. Typically, AIT comprises incremental doses to achieve high 
cumulative doses of allergen extracts, mostly via the subcutaneous (SCIT) and often via the 
sublingual/mucosal route (SLIT), to induce a state of sustained tolerance2,3 4. Regarding the 
apparent heterogeneity in the field of AIT and its current coming-of-age transformations, it 
seemed appropriate and timely to provide a state-of-the-art position paper on adjuvants in AIT. 
This EAACI-task force thus aimed at providing a current and transparent overview on currently 
used adjuvants and formulations in AIT, and especially highlights unmet needs. 
Mechanistically, AIT counteracts the predominant Th2 immunity in allergy by several well-
described immunological mechanisms, altogether resulting in tolerance towards the natural 
exposure of the allergen. The immunological changes associated with successful AIT include the 
generation of allergen-specific regulatory T and B cells 5-8, both a source of the 
immunomodulatory cytokine IL-109, and/or CD4 cell subsets including Th1 cells10, generation of 
regulatory DCs 11, inhibition of Th2 responses, and reduction of infiltrating inflammatory cells 5. It 
may be not necessarily associated with decreases of allergen-specific IgE levels, and the 
induction of allergen-specific IgA and IgG. The most classical hallmark of AIT is the increase of 
allergen-specific IgG4, the only anti-inflammatory IgG subclass. Allergen-specific IgG, particularly 
IgG4 may i) act as a blocking antibody, trapping the allergen before it can crosslink surface-
bound IgE on allergy effector cells including mast cells and basophils, for instance as neutralizing 
antibody in nasal fluids 12; ii) interact with inhibitory IgG receptor FcRIIb and downregulate IgE-
mediated signalling 13,14; iii) repolarize macrophages from their allergenic phenotype M2a into 
tolerogenic M2b, characterized by IL-10 and CCL1 secretion 15. Disappointingly, none of the 
described cellular or humoral biomarkers has so far been able to predict the clinical outcome of 
AIT 16, neither in SCIT nor SLIT 17. Current publications explicitly aiming to fill this gap recently 
added several candidates to the list of potential biomarkers, including nasal IgG4 12, early IL-10 
producing B-cells 18, IL-35 19,20, follicular regulatory T cells 21, or  human lipocalin-2, a biomarker 
for the clinical  response in grass pollen and house dust mite SLIT 22.  
Overall, it is unequivocal that the AIT products applied in daily practice have clinical efficacy but 
there are still some drawbacks related to undesired side effects, low efficacy, long treatment 
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2. Definition of “adjuvant“ in AIT 
Placebo-controlled studies conducted both in Europe and the United States (US) have supported 
both the efficacy and safety of a variety of AIT modalities. However, over the decades, the 
products as well as routine clinical practices of allergists who administer AIT have considerably 
diverged between the US and Europe 25. To this end, nearly all products approved for SCIT in the 
US are aqueous extracts. Compared with aqueous products in the US, adjuvant-absorbed 
suspensions are preferentially used in Europe which could delay systemic absorption and reduce 
risk of severe anaphylactic reactions. Furthermore, it has been previously hypothesized that 
European vaccines “may gain more acceptance because of increasing regulatory approval and 
lower numbers of injections” 26. However, head-to-head studies of aqueous versus non-aqueous 
formulations which could address the relative safety profiles of these products are lacking.
In Europe the allergoid approach has been widely undertaken under the assumption to minimize 
the risk of side effects. Allergoids are chemically-modified allergens to reduce the IgE binding, but 
they are usually not applied without adjuvants. In the adjuvants approach, allergens are 
physically precipitated, creating a depot at the injection site, while simultaneously enhancing 
immunogenicity (Table 1) (Figure 1). The safety of allergoids 27 allows fast updosing 28 and 
induction of  IL-10 and protective  antbodies29, but this strategy can be corroborated by the choice 
of adjuvans30. In this paper we thus focus on the adjuvants approach, rather than on the allergoid 
concept. Table 1 also illustrates that the choice of methods presently used for formulation of 
marketed AIT products is quite limited. Adjuvants also may enhance the efficacy of AIT by 
polarizing the immune response towards a protective immune response. Adjuvants typically 
comprise danger signals, leading to inflammation and enhancing the subsequent immune 
response against the applied allergen. In principle, AIT adjuvants using the TLR-based vacuolar 
pathway or the aluminium-based cytosolic pathway and lead to enhanced cross-presentation by 
DCs 31.  Mouse studies indicate that different adjuvants may induce distinct inflammatory 
signatures: aluminium hydroxide (Al(OH)3) and microcrystalline tyrosine (MCT) via NAPL3 
inflammasome activation 32 induce caspase-dependent IL-1beta secretion in a TLR independent 
manner 33 ; aluminium hydroxide induces a release of IL-5 as an initiator of eosinophilic 
inflammation; monophosphoryl-Lipid A (MPL) acts via TLR4 induced high levels of TNF-alpha, IL-
1 alpha and IL-6 34. These divergent immune mechanisms are especially expressed in the onset 
of AIT and whether these initial effects are per se beneficial or detrimental, or affect the outcomes 
or efficacy of AIT is not known and should be fully investigated. Therefore, each adjuvant acts via 
distinct immunological mechanisms, modulating adaptive as well as innate immune responses, all 
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European SCIT products, mostly Al(OH)3, much less frequently MCT, MPL, or other adjuvants 
are applied, as listed in Table 2 and shown in Figure 2A for grass pollen SCIT as an example. 
Besides SCIT (respiratory and venom allergies) and SLIT (respiratory allergies), principally the 
epicutaneous (in food allergy) 35, intravenous (in drug, biologics and hormone allergy 36), 
intralymphatic 37, and oral routes are possible 38. The adjuvant choice may be decisive for 
optimally targeting the allergens to the lymphoid organs depending on the route of administration. 
Adjuvant formulations for subcutaneous, mucosal, and percutaneous AIT applications presently 
addressed in registered clinical trials and listed in the official databases EudraCT and 
ClinicalTrials.gov, are presented in Table 3. The overview makes clear that most SCIT trials with 
allergen extracts, as well as clinical trials with allergoids, hypoallergens, and fusion proteins, use 
aluminium salts as adjuvants. 
In terms of mucosal applications (SLIT, oral and intranasal) and epicutaneous AIT, most 
preparations in clinical practice do not contain adjuvants. Notably, there is increasing activity in 
introducing various adjuvant candidates for the mucosal route, like MPL, allergen-conjugates to 
adjuvants, virus-like particles (VLPs), or particulate allergen delivery systems such as chitin and 
cellulose, or for percutaneous application polylactic acid or silver particles in clinical trials (Table 
3). 
However, a plethora of alternative adjuvants and formulations of allergen extracts has been 
developed and are in the preclinical pipeline awaiting introduction into clinical testing and practice 
(suppl. Table 1). They may change our way of performing AIT in the future. Immune-modifying 
platforms such as allergen-displaying VLPs, or cytosine-guanine dinucleotide (CpG)-motifs, 
adjuvants like MPL combined with Al(OH)3 or with MCT, or spiking of molecular allergens with 
natural micronutrients, may improve the efficacy of AIT and more efficiently direct the 
immunological response toward a protective response or immunological tolerance 39. Delivery 
systems, such as liposomes and microspheres as well as adjuvants such as Toll-like-receptor 
agonists [e.g. nonmethylated CpG-motifs derived from bacterial DNA] have been tested in clinical 
phase II and III trials demonstrating encouraging clinical effects 40 (suppl. Table 1). A high-density 
display of allergens on virus-like particles enhances the immunogenicity and at the same time 
seems to reduce potential anaphylactic reactions 41.
The assessment of efficacy and safety of AIT adjuvants and formulations is hampered by the lack 
of head-to-head comparison studies, or inclusion of placebo controls in trials. Dose finding 
studies are on-going to fulfil the EMA-Guideline on the Clinical development of products for SIT 
for the Therapy of Allergic Diseases (CHMP/EWP/18504/2006) 42. These studies –together with 
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allergen products  and may pave the way for a transparent declaration of allergen dosages and 
extract composition, but also of adjuvants. 
3. Adjuvants in marketed products 
To enable a direct comparison among adjuvants and formulations currently used in AIT trade 
products on the market, a survey of the industry was performed specifically addressing the 
compositions for SCIT with grass pollen extracts. Leading pharmaceutical companies with 
marketed grass pollen products were approached by letters in November 2017, and asked to fill-
in the supplied Tables to be published in this position paper of EAACI. Responses filled-in in the 
Tables (Table 2 and suppl. Table 2) were gathered between December 2017 and March 2018 
and were included in unmodified form (as stated by the companies) in the Tables. All industry 
representatives supplying the data were informed about our parallel request to all competing 
companies. Eight of 11 approached companies responded and listed single to several products, 
totalling 21: AllergoPharma (Allergovit®), ALK (Alutard SQ; ALK7/Start SQ; AVANZ®; Pangramin 
Ultra; Aquagen 100; IRIS), Allergy Therapeutics (Pollinex® Grass, TA Graser top, MATA PFS; 
Pollinex® Quattro Grass/MPL; Pollinex® Quattro Grass/MCT; Tyrosine TU top Grass), HAL 
Allergy BV (Purethal® grasses), LETI (Depigoid grass; Depiquick), LOFARMA SpA (LAIS-in), 
ROXALL (CLUSTOID; Deposit; Allergovac Depot; Allergovac Polimerizado), STALLERGENES 
(Alustal®; Phostal®), as collectively illustrated in Table 2. ANERGIS SA, ASIT biotech and 
Biomay AG, at the time of the survey, had no grass pollen product on the market. 
The classical adjuvant Al(OH)3 was used in 14 of 21 listed grass pollen SCIT products, Calcium 
phosphate (CaP) in two, MCT in three, MPL in one (Figure 2A). Further, mannitol was contained 
in two products, phenol in five, which serve as stabilizers rather than adjuvants.
The number of injections depended on the schedules (3-5 years) and ranged from n=18-63 
(mean n=30) in formulations with Al(OH)3 (suppl. Table 2), between n=39-63 (mean 51) in one of 
the two products adjuvanted with CaP, between n=18-36 (mean n=24) for products with MCT, 
and n=12 for the single product adjuvanted with MPLA (Figure 2B; suppl. Table 2). 
In most cases, the ratio of allergen : adjuvant is not declared or not known (Table 2 and suppl. 
Table 2). In a single case, the precise ratio of group 5 allergens to adjuvant is revealed in the 
columns where we requested mg/mg declaration. The nomination of major allergens is 
advantageous as allergen extracts also contain non-protein compounds, and non-allergens which 
do not contribute to the specific activity of the extract. Therefore, instead of whole protein, or 
weight-by-volume (Noon unit), the protein nitrogen unit (PNU; quantity of nitrogen extractable 
from 1 µg of pollen) was introduced. Today, measures reflecting the biological activity of the 
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allergen units (BAU) have been suggested for optimization of allergen standardization 43. It is, 
however, challenging to determine this activity for allergoids. The need of consistent quality in 
manufacturing for reliable composition of allergen extracts in terms of major and minor allergens, 
is increasing and supported by novel standardization methods 44.
4. Aluminium compounds
Aluminium hydroxide is the most widely used adjuvant for SCIT introduced since 1937, and 
aluminium and its chemical derivatives strongly support the immunogenicity of antigens 45 46. 
Since it is the oldest adjuvant in AIT, most facts, figures and toxicity studies are available for 
Al(OH)3. Mechanisms involved include both a depot effect (i.e. slow release of the allergen, 
formulation of the allergen as particles to target antigen presenting cells (APCs)) as well as 
interaction with the innate immune system: e.g. by stimulating the release of damage-associated 
molecular patterns (DAMPs) 47, by activating inflammatory DCs48 or by metabolic reprogramming 
DCs 30, while the previously reported dependence from inflammasome activation32 recently was 
disputed33. More than 90% of all registered AIT products contain Al(OH)3 in which the European 
Pharmacopoiea limits the aluminium content to 1.25 mg per parenteral dose 49. The products 
currently registered (in Germany) contain 0.113 to 1.135 mg/ml Al(OH)3, during up-dosing and 
maintenance phase of SCIT. The therapeutic allergens are adsorbed to the adjuvants and 
Al(OH)3 is characterized by a high degree of insolubility; this is actually a wanted effect since it 
results in a depot of the therapeutic allergen and increases the therapeutic success of AIT. The 
consequences are slow resorption and delayed bioavailability of the antigen. A study in rabbits 
using radioactive labelled Al(OH)3 demonstrated that within 28 days 17% of the intramuscularly 
applied Al(OH)3 was resorbed and 6% was excreted through the kidney 50. A maximal 
concentration of 2 g/l of aluminium was observed in plasma. In one study, rabbits were 
subjected to 20 subcutaneous applications of aluminium lactate 51. The no observed effect level 
(NOEL) was calculated to be 0.7 mg/kg per day. Interspecies extrapolation yielded a human 
equivalent dose of 23 mg aluminium for a 70 kg adult, which is more than 20-fold higher than the 
aluminium dose in a single shot in available therapeutic allergen preparations. Presently, novel in 
vitro methods are developed to test the toxicity of aluminium 52,53, for instance the Paul-Ehrlich-
Institute (PEI, Langen, Germany) develops toxicokinetic models in vitro, -in silico, and in rats to 
determine intramuscular absorption of Al(OH)3 for a risk prediction in humans 54, 55.
Among all pharmaceutical, occupational and consumer exposures potentially representing a 









This article is protected by copyright. All rights reserved
inter-regional variation in the daily aluminium uptake, and a range between 0.2 to 1.5 mg/kg per 
week was calculated for adults. For children a maximal dose of 0.7 to 2.3 mg/kg per week was 
reported by the European Food Safety Authority in a news release 57. The health risk of 
aluminium originating from food has been evaluated several times by international experts 
including the Joint FAO-WHO Expert Committee on Food Additives (JECFA) and the AFC Panel 
(panel on food additives flavourings processing aids and materials in contact with food) of the 
EFSA 58,59. EFSA calculated the tolerable weekly intake (TWI) of aluminium from all food sources 
at 1 mg/kg body weight per week 58. 
Although most of the aluminium is eliminated through the kidney, this is a slow process and due 
to the long half-life a net-accumulation occurs. The lifelong body burden of aluminium is about 1% 
to 2% of the resorbed dose, which is estimated as 5 to 60 mg of aluminium 60,61, and with a higher 
risk in certain occupations 59. Most of the aluminium is stored in the skeletal system, and about 
1% is stored in the brain 62,63. During a regular 3-year AIT cycle consisting of 8 applications per 
year, and with an allergen containing 0.5 mg aluminium per dose, an estimated total dose of 12 
mg aluminium is administered. Calculating conservatively 2% retention, this would result in a life-
long accumulating dose of 0.24 mg aluminium from AIT. Suppl. Table 2 illustrates differences in 
AIT regimens recommended by different providers.
The following aspects need to be considered:
 The most known local reactions are the development of granuloma. This is dependent 
on the type of alum and extracts, and the application 64,65.
 Sensitization. Contact allergies to aluminium are rare 66-68, but delayed type 
hypersensitivity may play a role in granuloma formation 64. 
 There is a debate that Al(OH)3 may increase the allergy risk to the adsorbed allergen 69. 
This is primarily based on animal models where Al(OH)3 is used as a Th2 adjuvant. 
However, it is difficult to extrapolate from the mouse to the human situation. Vaccinated 
patients uncommonly develop an IgE-mediated allergic response to the vaccine-antigen 
70,71, except perhaps food allergens 72. No evidence was reported that typical childhood 
vaccines such as M. bovis Bacille Calmette-Guerin, pertussis, influenza, measles, 
mumps, rubella or smallpox pose a risk for the later development of atopy 73 which, 
however, are mostly not adjuvanted with aluminium  71. Furthermore, a long term effect of 
Al(OH)3 containing AIT, like with other adjuvants,  is the induction of an IgG response 
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 Acute toxicity. As a consequence of high aluminium exposure symptoms of acute toxicity 
including neurotoxic effects (encephalopathy), bone marrow effects (anaemia), and on 
reproduction have been extensively studied in animal models. In humans, acute toxicity 
was particularly observed in patients with chronic kidney disease following long-lasting 
haemodialysis: This syndrome is known as dialysis encephalopathy syndrome (DES) and 
occurred particularly in the 1970´s due to exorbitant aluminium uptake from the use of 
aluminium in the dialysis bath. Patients reached plasma levels between 200 to 500 g/l 
associated with onset of brain malfunction at >30 g/l 62,65. There have been no 
phamacovigilance signals for acute toxicity linked to AIT.
 Long-term toxicity. There is a debate about the development of breast cancer, 
Alzheimer’s disease, multiple sclerosis, autoimmunity 76,77 and other diseases in the 
context of aluminium burden. The German Institute of Risk Assessment (BfR) could not 
detect a relationship between the increase of aluminium intake from foods, medication, or 
cosmetic agents and the development of Alzheimer’s disease 78, while a recent meta-
analysis determined a 71% increased risk (OR: 1.71, 95% confidence interval (CI), 1.35–
2.18) 79.  The use of newer staining methods like Lumogallion 80 have demonstrated to be 
useful to trace aluminium in tissues and may contribute to the necessary collection of 
more evidence. 
 As much more data and studies are available for Al(OH)3 than for any other adjuvant in 
AIT (which need to be studied in more detail), the detailed description of current 
knowledge on Al(OH)3 may give the impression of an unfavourable benefit risk balance 
as an adjuvant, however no definite conclusions can be drawn at this point in time. Recent 
data derived from a model for aluminium toxicokinetics in rats give hope that individual 
vaccinations also in human tissue may not lead to measurable changes in the aluminium 
load.
  After several years of subcutaneous immunotherapy a substantial, but clinically not 
relevant increase in the aluminium concentration in the bone has to be expected. Reliable 
extrapolations from results in rats to humans will be possible with the help of a physiology-
based model under development. However, the aluminium toxicity data combined with 
manifold repeated injections of Al(OH)3 in AIT (see suppl. Table 2), prompt us to carefully 
monitor the known and emerging pros and cons of all adjuvants. Many vaccines (e.g. 
diphtheria, tetanus, pertussis, hepatitis B, pneumococcal and meningococcal vaccines) 
contain Al(OH)3, because an effective vaccination would not be possible without this 
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are convinced of the survival benefit for mankind and reject any ongoing anti-vaccine 
discussion. 
5. Monophosphoryl Lipid A
MPLA, precisely 3-O-desacyl-4'-monophosphoryl lipid A (MPL®), is a low-toxicity derivative of the 
lipid A region of lipopolysaccharide (LPS), that retains the immunologically active lipid A portion of 
the parent molecule. While the toxicity associated with LPS prohibits its clinical use, MPL has 
been developed as a vaccine adjuvant in anti-infectious, anti-cancer vaccines 81 (for instance, 
MPL is contained in the FDA- and EMA-approved marketed Human Papilloma Vaccine by GSK) 
and in AIT, allowing lower injection numbers mimicking rather the vaccine approach.
MPL is extracted from lipopolysaccharide (LPS or endotoxin) produced by the Re mutant of a 
rough strain Salmonella minnesota R595. Lipid A, a disaccharide with fatty acid side chains, is 
the component responsible for the endotoxic activity of LPS. Removal of one phosphate group 
from lipid A produces MPL (alias MPLA) which has reduced toxicity while retaining the ability to 
stimulate the immune system via TLR4. Synthetic lipid A (MPLAs) from E. coli is produced 
synthetically.
MPL in mouse studies 82 skews the immune response toward Th1 and Treg pathways, and it has 
been suggested that MPL improves vaccine immunogenicity by enhancing APC maturation. MPL, 
like CpG-ODN, imidazoquinolines and adenine derivatives acting via innate sensors represent 
improvements in AIT by interfering with pathogenic Th2 cells and promoting Th1 differentiation 83.
Both LPS and MPL are TLR4 agonists. TLR signalling is involved in activating innate and 
adaptive immune responses and plays a critical role in inflammation-induced diseases. 
Dysregulation of this signalling pathway can result in disturbance of epithelial layer homeostasis, 
caused by chronic inflammation and excessive repair responses. MPL and several other agents 
have been approved for anti-cancer vaccines as there is now substantial evidence for the benefit 
of targeting of this pathway in cancer 84.
LPS and MPLA signal through TLR4 which has two different TLR adaptors, MyD88 and TRIF. 
The reduced toxicity of MPLA is attributed to the preferential recruitment of TRIF upon TLR4 
activation, resulting in decreased induction of inflammatory cytokines.
MPLAs activates TLR4 but does not activate TLR2 reflecting the high purity of this synthesized 
compound. MPLAs contains 6 fatty acyl groups, while MPL purified from bacteria contains a 
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Combining distinct immune stimulants in adjuvants can even further improve the quality of the 
immune response to the vaccine. A unique mechanism of molecular and cellular synergy 
between MPL, and a saponin, QS-21, the constituents of the Adjuvant System AS01, has been 
reported 85. AS01 is part of the first malaria vaccine candidate and a herpes zoster vaccine that 
has recently received marketing authorization in a centralised procedure throughout the EU 
(21.3.2018). This mechanism, previously described for infections, illustrates how adjuvants trigger 
naturally occurring pathways and may improve the efficacy of AIT. Vice versa, the adsorption of 
allergoids and MPL to MCT in formulations for use in AIT suggested that it could be an alternative 
adjuvant depot for some infectious disease antigens 86 
Likewise, attempts were made to combine MPL with aluminium salts in the adjuvant system AS04 
in papilloma vaccines 87. More recently, it was demonstrated that combining MPL plus aluminium 
salts, or MPL plus muramyl-dipeptide (MDP), a NOD-like receptor (NLR) agonist exerted additive 
effects on the magnitude and quality of humoral responses towards HIV envelope antigens 88.
Due to the dual action of stimulating the immune system, a tyrosine-absorbed and MPL 
adjuvanted AIT was clinically effective after only four injections given pre-seasonally 89 and, in 
another study, contributed to the control of asthma during the pollen season 90. An ultra-short 
course of ragweed MATA MPL (short ragweed pollen allergoid adsorbed to L-Tyrosine + MPL) 
was efficacious in reducing allergy symptoms in patients with seasonal allergic rhinitis and was 
well tolerated 91. Ultra-short grass pollen AIT adjuvanted with MPL achieved specific bronchial 
tolerance as well as increased IgG4 levels (median before SCIT 0.34 to 11.4 kU/L after SCIT), 
whereas the total and specific IgE levels remained unchanged 92. Especially in the presence of 
MPL, the allergenicity of an employed allergoid was sharply reduced when compared to the 
native allergen, while its immunogenicity was largely retained 93. Booster AIT, using MCT-
absorbed allergoids containing the adjuvant MPL, effectively prevented re-occurrence of 
symptoms in patients with grass pollen-induced allergic rhinoconjunctivitis who had completed a 
successful course of any grass pollen AIT at least 5 years before enrolment, compared to control 
patients who received symptomatic medication 94.
The following aspects need to be considered:
 The most common adverse effects of MPL adjuvanted AIT are transient and local, such as 
redness, swelling and pruritus at the injection site 95. 
 However, also anaphylactic shock after administration of a pollen extract allergoid 
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 Since MPL was introduced only in 1999, more data are needed to reveal any potential 
toxicity.  
Overall, detoxified lipopolysaccaride (MPL-A), MPLAs, CpG-ODNs, imidazoquinolines and 
adenine derivatives acting via innate sensors represent improvements in therapeutic vaccinations 
for allergy as they are able to interfere with pathogenic Th2 cells with eventual induction of Th1 
differentiation and enhancing IgG responses 83,97. Furthermore, the use of explicit anti-Th2 
adjuvants like MPL 89,98 instead of adjuvants like aluminium compounds 69 might well help to 
improve current AIT protocols, potentially also of SLIT 99.
6. Microcrystalline tyrosine
Tyrosine is an amino acid that in crystalline form can be used as a biodegradable adjuvant with 
depot effect. In a mouse model, MCT was recently compared head-to-head with Al(OH)3 33, 
where it induced fewer anaphylactic reactions. In the same paper the immune mechanism of 
MCT as an adjuvant was addressed for the first time. In analogy to Al(OH)3, MCT provoked 
caspase-dependent secretion of IL-1β from cultured human monocytes, and in a model with 
immune-signalling-deficient and TCR-transgenic mice it was concluded that the inflammasome 
activation did not affect functionally the innate inflammatory or specific immune responses. In 
contrast to the LPS-derived MPL, MCT does not act via TLR4 signalling 33. 
MCT induced in mice less IL-4 and IgE formation than aluminium. It is also applied safely in 
preclinical models of malaria vaccines 100,101.  Furthermore, MCT has been shown to be beneficial 
in influenza vaccination when compared to Al(OH)3 102, where it enhanced antibody responses 
towards this vaccine.
When AIT effects on IgG4 induction were compared among the non-adjuvanted US product 
(Hollister-Stier®, Spokane, WA, US), and adjuvanted European products either using MCT 
(Tyrosine®, AllergyTherapeutics, UK) or Al(OH)3 (Novo-Hellisen®, AllergoPharma, Reinbeck, 
Germany) (Park), the US product showed the highest potency in inducing IgG4 103. However, in 
this study only patients without adverse side effects were included, thereby precluding any 
conclusions about simultaneous safety 103.
The following aspects need to be considered:
 At present, and since its introduction into AIT in 1970, there are no specific safety 
concerns known for MCT. 
 It can be anticipated that this fully biodegradable adjuvans will also in future studies not 
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7. Calcium-Phosphate
As an adjuvant calcium phosphate was developed 40 years ago as an adjuvant 104. It has been 
included in vaccines against various infectious diseases such as diphtheria, tetanus, pertussis 
and poliomyelitis. It was shown to be well tolerated in humans, and even more efficacious than 
Al(OH)3 when used as part of a booster vaccine for DT (diphtheria/tetanus) 105. 
Approved by the World Health Organization, CaP was further used in combination with allergens 
for hyposensitization purposes, based on the observation that it induces IgG, but not IgE 
responses. CaP is currently commercially available in Europe as a component of subcutaneous 
allergy vaccines in combination with grass pollen or mite extracts 106, 107 The aqueous allergen 
extracts are adsorbed onto the particulate CaP microcrystals. Allergen loading is thus thought to 
occur by passive adsorption, but also following encapsulation during particle formation. As a well-
tolerated adjuvant, CaP has been proposed as a substitute to aluminium-based adjuvants in 
allergic humans and dogs 108. A review of the present evidence suggests that CaP particles re-
introduce a more balanced immune response when compared with aluminium salts, known to 
elicit a Th2 biased humoral immune response 105, 82. 
Mechanisms of CaP in AIT include a depot effect with a slow release of the allergen. In addition, 
the adsorption of allergens onto CaP microcrystals as particles also facilitates the uptake by 
phagocytic cells (i.e. monocytes, macrophages, DCs), thereby enhancing the immunogenicity of 
protein allergens, with the induction of strong IgG responses 109. As a mineral adjuvant, CaP also 
induces the NALP3 inflammasome, resulting in the secretion of IL1 and IL-18 pro inflammatory 
mediators.  
 
The following aspects need to be considered:
 CaP is a compound present in many living organisms. As such, it is biocompatible and 
well tolerated by most patients. Common side effects include local reactions at the site of 
administration. 
 More data are needed to exclude any potential toxicity. 
 More studies are needed to support its efficacy as compared to other adjuvants.  
Conclusion
AIT is applied in patients who are hypersensitive to an allergen and at risk for adverse immediate 
type reactions. However, quality, efficacy, safety and tolerability of AIT as the only disease-
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allergen as a depot at the injection site thereby reducing the risk for systemic anaphylaxis, and 
also prolonging their availability for the immune cells. 
The Task Force’s review further revealed that, at present, only a limited number of adjuvants are 
applied in AIT vaccines. In marketed formulations aluminium compounds are predominant in 
Europe albeit the fact that aspects concerning health safety of aluminium have been 
controversially discussed. The immune mechanisms of the major adjuvants, Al(OH)3, MPL and 
MCT have only been addressed in recent years (while others are still missing), and explain their 
reported contrasting immune profile: aluminium, MCT and MPL induce high levels of blocking 
antibodies and regulatory T-cells; aluminium hydroxide initially boosts a Th2 response, while MPL 
and MCT induce early skewing towards a Th1 response; all adjuvants induce varying 
inflammation suggesting a hierarchy of biocompatibility MCT>CaP>MPL>Al(OH)3.
The preclinical pipeline is filled with interesting novel options in terms of adjuvants and carrier 
systems, and immune-modifying molecules, being more biocompatible and allowing development 
of improved immunization schedules with greater comfort for the patient. All reported strategies 
are of the highest importance to improve the insufficient adherence of patients in AIT independent 
of route of administration as SCIT or SLIT, resulting in only 18% of users reaching the minimal 3 
year course duration in an earlier study 110, while in studies with other products adherence rates 
up to 50% were reported 111,112. The discussion is ongoing whether shorter treatment regimens 
could improve adherence 113, as most dropouts (with alumiunium or tyrosin adjuvanted products) 
occurred already in the first year 111, paradoxically with cluster build-up and rush schemes, 
younger age, and, interestingly, to longer disease duration 114. In SLIT, forgetfulness may be the 
most important reason for dropouts 115. Overall, adherence is a severe problem in all of the 
currently marketed AIT products, underlining the need for optimising AIT with novel adjuvants and 
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Legends
Figure 1: Adjuvants enhance B- and T- cell responses to the antigen by various mechanisms. 
Adjuvanted antigens exploit activation of Toll like receptors (TLRs) on B cells, crosslinking of B cell 
receptors (BCR) by particles such as VLPs, and depot formulation to prolonge antigen stimulation. 
Further, adjuvanted antigen depots prolonge stimulation of DCs, targeting and enhancing uptake 
by dendritic cells (DCs), finally leading to activation of T-cells, which then help B-cells to become 
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Figure 2. Adjuvants in grass pollen AIT marketed in Europe. A) Percentage of products using Al(OH)3, 
MCT, CaP, or MPLA as adjuvant in grass AIT; B) Average number of injections with grass pollen AIT 
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Table 1: The contents and specification of AIT products 
Components Characteristics Chemical modification 
Allergen 
extracts 
Remain aqueous, native; used 
in SLIT and in United States  
for SCIT  
 none 
Allergoids Chemically modified allergens 
with reduced IgE binding,  
and enhanced immunogenicity, 
used for SCIT in Europe 
 Formaldehyde  
 Glutaraldehyde  
 Calcium cyanate 
Adjuvants *)  Achieve physical allergen depot 
for enhanced safety and 
immunogenicity, used for SCIT 
in Europe 
 Aluminium hydroxide  
 Calcium phosphate  
 Microcrystalline Tyrosine 
(MCT) 
 Monophosphoryl Lipid A 
(MPLA) 










Table 2: Detailled list on product informations for subcutaneous AIT products by industry. 
Physical properties of 
the adjuvant 






form density particle size
Allergopharma Allergovit Grasses Europe Aluminum-hydroxide Alum Al(OH)3 78.0 g/mol in suspension n.discl. n.discl. 




Phenol, water for 
injections
n.discl. Al(OH)3 n.discl. n.discl. n.discl. n.discl. 





n.discl. Al(OH)3 n.discl. n.discl. n.discl. n.discl. 






n.discl. Al(OH)3 n.discl. n.discl. n.discl. n.discl. 






n.discl. Al(OH)3 n.discl. n.discl. n.discl. n.discl. 
ALK Aquagen SQ n.discl. Mannitol
Water for injections
n.discl. n.discl. n.discl. n.discl. n.discl. n.discl. 











n.discl. n.discl. n.discl. n.discl. n.discl. n.discl. 
Allergy 
Therapeutics
Pollinex Grass, TA 




























MCT, L-tyrosine C9H11NO3 181.19 Da Crystalline n.discl. 20µm
Allergy 
Therapeutics






MCT, L-tyrosine C9H11NO3 181.19 Da Crystalline n.discl. 20µm












Al(OH)3 78.0 g/mol white amorphous powder 2.42 g/cm
3 n.discl. 
LETI Depigoid grass n.discl. Aluminium hydroxid Alhydrogel Al(OH)3 78.0 g/mol depigmented, 
glutaraldehyde 
polymerized, chemically 






LOFARMA SpA LAIS-in Europe Calcium phosphate n.discl. n.discl. n.discl. depigmented, glutaraldehyde n.k. about 100 nm
ROXALL CLUSTOID Germany-
Austria-Italy
Aluminium hydroxide Alhydrogel 2% Al(OH)3 78.0 g/mol Hydrogel (white gelatinous 
precipitate), Fibrous 
primary particles
2.42 g/cu cm 1-10 µm
ROXALL Deposit Germany Aluminium hydroxide Alhydrogel 2% Al(OH)3 78.0 g/mol Hydrogel (white gelatinous 
precipitate), Fibrous 
primary particles
2.42 g/cu cm 1-10 µm
ROXALL Allergovac depot Spain-
Portugal-
Italy
Aluminium hydroxide Alhydrogel 1.3% Al(OH)3 78.0 g/mol Hydrogel (white gelatinous 
precipitate), Fibrous 
primary particles






Aluminium hydroxide Alhydrogel 1.3% Al(OH)3 78.0 g/mol Hydrogel (white gelatinous 
precipitate), Fibrous 
primary particles
2.42 g/cu cm 1-10 µm
STALLERGENE
S
Alustal® n.discl. Aluminium hydroxide n.discl. Al(OH)3 78 g/mol n.discl. n.discl. n.discl. 
STALLERGENE
S
Phostal® n.discl. Calcium phosphate n.discl. Ca3(PO4)2 310 g/mol n.discl. n.discl. n.discl. 
4.) DPP = biological unit (1 DPP corresponds to 1 HEP of native allergen extract after depigmentation and polymerization /allergoidisation; HEP, histamine equivalent in prick testing 
3.) mgeq: mg equivalent. The  group 5 major allergen content is estimated before allergoidization. The adjuvant is aluminiumhydroxide, the Al3+ content has been calculated.
2.) n.k. not known
1.) n.discl. - non d+J4isclosed
*) unique numerical identifier assigned by the Chemical Abstracts Service)
**) permanent identifier for a depositor-supplied molecule found in the PubChem Substance database
***) Molecular Design Limited Number.
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Table 3.  The clinical pipeline of adjuvants in allergen specific immunotherapy: 
registered clinical trials. A systematic review of the literature was performed in PubMed in 
06/2018 for the preclinical trials using the terms “delivery system”, “adjuvant” and “allergen”, 
and by search of databases such as European clinical trials database EudraCT and 
ClinicalTrials.gov, using the term “allergy” and restricting to intervention trials. 
  
Type of Adjuvant Classification Allergen 
formulation 
Route No. of 
studies 
phase 
Mineral Salts Aluminium salts  Allergen extracts SCIT
1)
 > 40  2/3/4 
  Allergoids 
2)
 SCIT 2 2 
  Allergen fusion 
Proteins 
SCIT 4 2 





SCIT 1 2b 
 Calcium 
phosphate 
Allergen extracts SCIT 2 4 
Amino acids Tyrosine Allergen extracts, 
and 
SCIT >15 1/2/3/4 
  Allergoids    






SCIT >15 1/2/3 
CpG ODN 
5)




Allergen extracts SCIT 4 1/2 
Adjuvanted mucosal applications        
TLR activator MPL Allergen extract SLIT 1 1 
Conjugate Mannan  Allergoids SLIT
 6)
 2 2 
Microparticles Cellulose Allergen extracts intranasal, 
SLIT 
1 2/3 
 Chitin Allergen extracts intranasal 1 1/2 
Adjuvanted applications via the skin      
Microparticles PLA 
7)
 Allergen extracts epicutaneous 1 1 
Microparticles Silver  Allergen extracts epicutaneous 1 2 
      
 
Footnotes: 
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2.) Allergoids: Allergen extracts being polymerized by glutaraldehyde treatment, carbamylated or 
conjugated to mannan. 
3.) VLPs, virus-like particles 
4.) MPL, Monophosphoryl lipid A 
5.) CpG ODN, cytosine-phosphate-guanine oligodeoxynucleotides 
6.) SLIT, sublingual allergen-specific immunotherapy 
7.) PLA, polylactic acid 
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